Albert Bourla, Pfizer CEO (Leigh Vogel/Getty Images for Concordia Summit)
October 22, 2024 09:30 AM EDTUpdated 02:30 PM
Pharma

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Max Bayer

Pharma Reporter

Ac­tivist in­vestor Star­board Val­ue said Pfiz­er’s ex­ec­u­tives haven’t de­liv­ered on what they once called one of the best pipelines in the in­dus­try, and need to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times